Replies to post #236492 on Biotech Values

[DewDiligence]

MYOV/PFE—Xtandi 25% growth YoY and I buy the reasoning that combined sales force will result in much faster uptake.

Absolutely. There are many drug choices in the hormone-sensitive segment of the prostate-cancer market, so detailing plays a larger role than in most cancer indications.

PFE’s co-promotion will also make a big difference in the uterine-fibroid and endometriosis indications (when Orgovyx is approved for those indications).

[DewDiligence]

MYOV addendum (to #msg-160523240): Orgovyx seems like an almost perfect drug, and this makes me slightly uneasy despite the strong endorsement from PFE.